Biora Therapeutics Announces Funding Agreement with Existing Investors
2024年8月13日 - 5:05AM
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company
reimagining therapeutic delivery, today announced the signing of
financing agreements with its existing convertible notes holders.
“We appreciate the continued commitment of our existing
noteholders, who have agreed to an additional investment in Biora
that we expect will fund us to important milestones, including
anticipated partnering with large pharma,” said Eric d’Esparbes,
Chief Financial Officer of Biora Therapeutics. “Active pharma
collaborator interest in our BioJet™ platform, and recent promising
clinical trial results from our NaviCap™ platform, are drivers for
this commitment.”
About Biora TherapeuticsBiora Therapeutics is a
clinical-stage biotech developing two smart pill-based therapeutics
platforms: the NaviCap™ platform for colon-targeted treatment of
IBD, designed to improve patient outcomes through treatment at the
site of disease in the gastrointestinal tract, and the BioJet™
platform for oral delivery of large molecules, designed to replace
injection with needle-free, oral delivery for better management of
chronic diseases.
For more information, visit bioratherapeutics.com or follow the
company on LinkedIn or X.
About the NaviCap™ Targeted Oral Delivery Platform and
BT-600Biora’s NaviCap™ platform for colon-targeted
treatment of inflammatory bowel disease (IBD) is designed to
improve patient outcomes by increasing therapeutic activity in
tissue at the site of disease while also reducing systemic uptake
to improve safety.
BT-600 is a drug/device combination of the NaviCap™ device with
a proprietary liquid formulation of tofacitinib, for the potential
treatment of moderate to severe ulcerative colitis (UC). Biora’s
Phase 1 clinical trial of BT-600 successfully demonstrated delivery
throughout the colon in healthy participants, with lower systemic
exposure as desired. Biora’s presentation of Phase 1 data,
featuring key opinion leaders discussing the value of
colon-targeted drug delivery for improving efficacy in UC, can be
viewed here.
About the BioJet™ Systemic Oral Delivery
PlatformBiora’s BioJet platform for oral delivery of large
molecules is designed to replace injection with needle-free
delivery for better management of chronic diseases. The BioJet
platform uses an ingestible device the size of a multivitamin that
can transit through the digestive tract and deliver therapeutics
into the small intestine.
The BioJet device is designed to autonomously deliver a wide
range of large molecules, such as proteins, peptides, and nucleic
acids, in liquid formulation at multi-milligram doses, without
requiring complex reformulation.
Safe Harbor Statement or Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, which
statements are subject to substantial risks and uncertainties and
are based on estimates and assumptions. All statements, other than
statements of historical facts included in this press release,
including statements concerning the progress and future
expectations and goals of our research and development, preclinical
and clinical trial activities, including those involving BT-600 and
our NaviCap platform and model-based data projections for the
BT-600 program, and partnering and collaboration efforts with third
parties, are forward-looking statements. In some cases, you can
identify forward-looking statements by terms such as “envision,”
“may,” “might,” “will,” “objective,” “intend,” “should,” “could,”
“can,” “would,” “expect,” “anticipate,” “forward,” “believe,”
“design,” “estimate,” “predict,” “projects,” “projecting,”
“potential,” “plan,” “goal(s),” “target,” or the negative of these
terms, and similar expressions intended to identify forward-looking
statements. These statements reflect our plans, estimates, and
expectations, as of the date of this press release. These
statements involve known and unknown risks, uncertainties and other
factors that could cause our actual results to differ materially
from the forward-looking statements expressed or implied in this
press release. Such risks, uncertainties, and other factors
include, among others, our ability to innovate in the field of
therapeutics, our ability to make future FDA filings and initiate
and execute clinical trials on expected timelines or at all, our
ability to obtain and maintain regulatory approval or clearance of
our products on expected timelines or at all, our plans to
research, develop, and commercialize new products, the
unpredictable relationship between preclinical study results and
clinical study results, our expectations regarding allowed patents
or intended grants to result in issued or granted patents, our
expectations regarding opportunities with current or future
pharmaceutical collaborators or partners, our ability to raise
sufficient capital to achieve our business objectives, our ability
to maintain our listing on the Nasdaq Global Market, and those
risks described in “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in our
Annual Report on Form 10-K for the year ended December 31, 2023
filed with the Securities and Exchange Commission (SEC) and other
subsequent documents, including Quarterly Reports on Form 10-Q,
that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update
any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
law.
Investor ContactChuck PadalaManaging Director,
LifeSci AdvisorsIR@bioratherapeutics.com (646) 627-8390
Media ContactLiz RobinsonCG
Lifelrobinson@cglife.com
Biora Therapeutics (NASDAQ:BIOR)
過去 株価チャート
から 7 2024 まで 8 2024
Biora Therapeutics (NASDAQ:BIOR)
過去 株価チャート
から 8 2023 まで 8 2024